

Curriculum Vitae
2017

Jeffrey Dunn, MD, FAAN
Department of Neurology and Neurological Sciences
Stanford Neuroscience Health Center
213 Quarry Road
Palo Alto, California 94304
Work: 650 736-4310
Fax: 650 725-7459

Academic Appointments:

- 2013-present Clinical Professor of Neurology,
Neurology & Neurological Sciences; Stanford University; Stanford, CA
- 2008-2012 Clinical Associate Professor of Neurology,
Neurology and Neurological Sciences; Stanford University; Stanford, CA
- 1997-2007 Clinical Assistant Professor of Neurology,
Department of Neurology; University of Washington; Seattle, WA
- 1993-1996 Clinical Instructor in Neurology,
Medicine (Neurology); University of Washington; Seattle, WA
- 1992-1993 Chief Resident in Neurology,
Medicine (Neurology); University of Washington; Seattle, WA

Education:

- 1985-1989 Doctor of Medicine (M.D.),
Temple University School of Medicine; Philadelphia, PA
- 1984-1985 Research Associate in Molecular Immunology;
Fox Chase Cancer Center; Philadelphia, PA
- 1979-1983 Bachelor of Arts (B.A.), French Literature
Haverford College; Haverford, PA
- 1982 Institut d'Etudes Francaises; Avignon, France

Postgraduate Training:

- 1990-1993 Residency in Neurology
University of Washington; Seattle, WA
- 1989-1990 Internship in Medicine;
Eastern Virginia Graduate School of Medicine; Norfolk, VA

Licensure and Certification:

2016-present Diplomat recertification; with maintenance of certification MOC requirement; American Board of Psychiatry & Neurology #40439: www.abpn.com/verifycert

2004-2016 Diplomat recertification; American Board of Psychiatry & Neurology; # 40439

1994-2004 Diplomat, American Board of Psychiatry & Neurology; # 40439

1990 Diplomat, National Board of Medical Examiners; # 379589

2007-2017 Physician and Surgeon, California State; License # G88167

1993-2008 Physician and Surgeon, Washington State; License # 28894

1992-2018 DEA Registration, Schedules 2, 2N, 3, 3N, 4, 5; # BD285276

2005-present NIH Certified Principal Investigator for Research in Human Subjects

2016-present HIPAA Privacy for Clinical Researchers Certificate; LawRoom

2013-2017 CITI Collaborative Institutional training Initiative; Stanford University
Human Subjects Research Protections Curriculum Completion Ref #9993498

2009-2017 Medical Research Investigators Certification; Stanford University
CITI Collaborative Institutional Training Initiative; # 1111159

Clinical Teaching Responsibilities:

2008-present Neurology Clerkship Director
Department of Neurology and Neurosciences; Stanford University; Stanford, CA

2011-2016 Fellowship Director, Clinical Neuroimmunology
Department of Neurology and Neurosciences; Stanford University; Stanford, CA

2016-present Course Director, Annual Breakthroughs in Neurologic Therapies; San Francisco, CA

2008-2016 Ward and Consult Attending
Stanford University Hospital and Clinics; Stanford, CA

2008-2012 Preceptor, Neurology Residents' Clinic
Stanford University Hospital and Clinics; Stanford, CA

2004-2008 Preceptor, Multiple Sclerosis Fellowship
University of Washington: MS Hub and Evergreen MS Center; Seattle, WA

2000-2004 Ward and Consult Attending,
Puget Sound Veterans' Affairs Hospital Medical Center (U of W); Seattle, WA

Other Teaching Experience:

13 Jan 2017 HHD223 "CNS Demyelinating Diseases;" Stanford SOM: taped lectern lecture

11 Jan 2016 HHD223 Health & Human Disease Lecture; Stanford School of Medicine

01 Apr 2015 Q6 Neurology Lecture and Workshop; LK130: Stanford School of Medicine

31 Jan 2014 HHD223: Demyelinating Diseases. Lecture with test questions; Stanford SOM

30 Jan 2014 INDE 205: Advanced Clinical Skills Neurology Examination; Stanford SOM

08/14/13 PCAP Neuroscience Symposium 2013: DDx Muscle Weakness; Stanford SOM

1/31/13 INDE 205: Advanced Clinical Skills; Stanford University School of Medicine

1/28/13 HHD223 Health & Human Disease, Brain Block; with test questions: Stanford University School of Medicine

1/24/13 INDE 205: Advanced Clinical Skills; Stanford University School of Medicine

2012-present Founder, Clinical Neuroimmunology Case Conference Monday noon series

- 2008-present Department of Neurology and Neuroscience, Stanford University; Stanford, CA
 Division coordinator, MS-Clinical Neuroimmunology resident didactic series;
 Last series 27 April-25 2016: Clinical Neuroimmunology;
 Neurology and Neurosciences; Stanford University; Stanford, CA
- 2008-present Preceptor, MS and Clinical Neuroimmunology elective for housestaff
 Department of Neurology and Neurosciences; Stanford University; Stanford, CA

Fellows/Subspecialty Specific Trainees (Clinical Neuroimmunology):

- 2017-2018 Aaron Carlson, MD
 Clinical Fellow in Multiple Sclerosis & Clinical Neuroimmunology
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2016-2017 Luka Vlahovic, MD
 Clinical Fellow in Multiple Sclerosis & Clinical Neuroimmunology
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2015-2016 Lucas Kipp, MD
 Clinical Fellow in Multiple Sclerosis & Clinical Neuroimmunology
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2014-2015 Esther Melamed, MD, PhD
 Research fellow in Multiple Sclerosis & Neuroimmunology (clinic mentor)
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2012-2013 Alexandra Goodyear, MD, MA
 Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology;
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA

Hospital or Affiliated Administration and Committee Assignments:

- 2008-present Division Chief, Clinical Neuroimmunology,
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2008-present Neurology Clerkship Director,
 Department of Neurology and Neurosciences; Stanford University; Stanford, CA
- 2009-present Education Committee Member,
 Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2008-present Residency Ranking and Selection Committee; Department of Neurology;
 Stanford University; Stanford, CA
- 2016-present Course Director, *Breakthroughs in Neurologic Therapies* Annual Symposium;
 Departments of Neurology & Neurosurgery; San Francisco, CA
- 2010-2016 Fellowship Director, Clinical Neuroimmunology Fellowship Program;
 Stanford University Department of Neurology and Neurosciences; Stanford, CA
- 2017-present Chair, Steering Committee for PWD for required clerkship shelf exams;
 Stanford University School of Medicine; Stanford, CA
- 2009-2011 Steering Committee, Criterion Based Evaluation Initiative;

Stanford University School of Medicine; Stanford, CA

National Committee Memberships:

- 2015-present Member, Association for University Professors of Neurology (AUPN); #680
- 2014-2016 Vice President, Multiple Sclerosis Section, American Academy of Neurology
peer-elected from national membership; American Academy of Neurology
- 2014-2015 AAN MS and CNS Inflammatory Disease Topic Work Group TWG; AAN
- 2011-2014 Chair, MS Education Workgroup, Multiple Sclerosis General Section
American Academy of Neurology; St. Paul, MN
- 2013-2014 ACP Clinical Effectiveness Study Network OPT-UP Members
- 2010-2014 Executive Committee, MS General Section Councilor
American Academy of Neurology; peer elected 2010
- 2011-2013 ACP Repository Oversight Committee
Accelerated Cure Project for MS; Waltham, MA
- 2008-2011 Member, American Academy of Neurology MS Education Task Force
- 2008-present Member, National Consortium of Multiple Sclerosis Centers (CMSC)

Other Professional Positions held:

- 2013-present Clinical Professor of Neurology,
Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2008-2013 Clinical Associate Professor of Neurology,
Department of Neurology and Neurosciences; Stanford University; Stanford, CA
- 2004-2008 Founder and Chief Medical Officer,
MS Hub Medical Group and Evergreen MS Center; Seattle/Kirkland, WA
- 1996-2004 Founder and Medical Co-Director,
Overlake Multiple Sclerosis Clinic; Bellevue, WA
- 1993-2004 Attending Neurologist with Special Interest in Clinical Neuroimmunology,
Neurological Associates of WA; Bellevue/Kirkland, WA

Professional Society Memberships:

- 2016-present Member, Stanford Medicine Teaching and Mentoring Academy
- 2008-present Fellow, American Academy of Neurology
- 2009-present Member, Association of University Professors of Neurology (AUPN)
- 2006-present MS Section; American Academy of Neurology
- 2004-present Member, Consortium of Multiple Sclerosis Centers
- 2008-present Member, San Francisco Neurological Society
- 2008-2016 Member, Pan-Asian Committee for Treatment and Research in MS
- 2016-present Member, California Neurology Society; Sacramento, CA

Editorial Boards:

2013-2017 Reviewer, *Multiple Sclerosis Journal* (impact factor 4.472; 25/191 in Neurology)
2011-2013 *Journal of Neurological Sciences*
2008-2013 Ad-hoc Reviewer, *Continuum: Lifelong Learning in Neurology*
2008-2010 Publication Working Group; Acorda Therapeutics; Hawthorne, NJ
2008-2010 Publications Committee, CombiRx Study; sponsor NIH

Peer Reviewed Publications:

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Hauser S., et. al.,
OPERA II Clinical Investigators. *New England Journal of Medicine* 19 Jan 2017; 376; 3: 221-234

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G., et al., **CARE-MS II Investigators**. *Neurology* 2016; 87: 1985-1992

Interferon beta treatment requires B-cells for efficacy in neuro-autoimmunity. Schubert R., Hu Y.,
Kumar G., Szeto S., Abraham P., Winderl J., Guthridge JM, Pardo G., **Dunn J.**, Steinman L.,
Axtell R.C. *Journal of Immunology*, 2015; 194 (5): 2110-2116

Disease Modifying Therapies for non-relapsing Multiple Sclerosis: Absence of evidence does not
constitute evidence of absence. **Dunn, J.** *Neurol Clin Pract.* December 2013; 3 (6): 515-518

Mobility Concerns in Multiple Sclerosis- Studies and Surveys on US patient populations of
relevance to nurses. Lee, J., **Dunn J.** *US Neurology*; 2013; 9(1): 17-23

Lublin, F. et al. and **CombiRx Investigators**. Randomized study combining interferon and
glatiramer acetate in Multiple Sclerosis. *Ann Neurol* 2013 Mar; 73 (3): 327-340

The CombiRx Trial of Combined Therapy with interferon and glatiramer acetate in relapsing
remitting MS: Design and Baseline Characteristics. Lindsey, J. et. al. and **CombiRx
Investigators**; *Mult Scler Relat Disord*: 2012 April 1; 1 (2): 81-86

Alemtuzumab for patients with relapsing Multiple Sclerosis after disease-modifying therapy: a
randomized controlled Phase 3 trial. Coles AJ, et al. **CARE MS II Investigators**. *Lancet* 2012;
380: 1829-1839

Peripheral Blood Immune Cell Profiling Reveals Distinct Immunological and Clinical Phenotypes
in Neuromyelitis Optica. You, Y., Alonso, M., Axtell, R., Kurnellas M., Lebus D.,
Goodyear A., **Dunn J.**, Steinman L., Engleman E., Fire A., Boyd S., Han M.; in submission

Protective effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of
myelin oligodendroglial glycoprotein. Herges K, deJong BA, Kolkowitz I, Dunn C,

Mandelbaum G, Ro RM, Maini A, Han, MH, Killestein J. Polman C, Goodyear A, **Dunn J**, Steinman L, Axtell RC; *Multiple Sclerosis* 2012; 18 (4): 398-408

Dalfampridine: A Brief Review of Its Mechanism of Action and Efficacy as a Treatment to Improve Walking in Patients With Multiple Sclerosis; **Dunn J.**, Blight D. *Curr Med Res Opin.* 2011 Jul;27(7):1415-23

The impact of mobility impairment on the burden of caregiving in individuals with Multiple Sclerosis. **Dunn J.** *Expert Rev Pharmacoecon Outcomes Res:* 2010 Aug; 10 (4) 433-440

CMV Optic Neuritis with extensive tracking along the visual pathway: Pershing S, **Dunn J.**, Khan A, Liao YJ; *J Neuroophthalmology* 2009; 29 (3):223-226

Glatiramer acetate after induction therapy with mitoxantrone in relapsing Multiple Sclerosis: Vollmer, T., Panitch, H., Bar-Or, A., **Dunn, J.**, Freedman, M., Gazda, S.K., Campagnolo, D., Deutsch, F. and Arnold, D.: *Multiple Sclerosis* 2008; 14: 663-670

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS; Arnold, D.L., Campagnolo, D., Panitch, H., Bar-Or, A., **Dunn J.**, Freedman, M.S., Gazda, S.K., Vollmer, T: *J Neurol* 2008; 255: 1473-1478

Tovaxin for early relapsing Multiple Sclerosis Phase 2b placebo controlled trial of autologous T-cell vaccination in patients with Clinically Isolated Syndrome or relapsing remitting MS: Fox, EJ and The **TERMS Study Investigators:** *Multiple Sclerosis* 2008;14: S5-S27

A randomized, double blind, dose comparison study of Glatiramer Acetate in relapsing remitting Multiple Sclerosis; J.A. Cohen, M. Rovaris et al and the **9006 Study Group:** *Neurology* 2007 Mar 20; 68 (12):939-944

Results of a randomized, double blind, parallel group study assessing safety and efficacy of 40 mg vs. 20 mg of Glatiramer Acetate on MRI measured disease activity in relapsing remitting Multiple Sclerosis; J.A. Cohen, M. Rovaris, et al and the **9006 Study Group:** *Neurology* 2006; 67: 185

Gingko Biloba in the treatment of Alzheimer's Disease;
Dunn, J., Maidan, R. and Pallis, J.; *Alternative Medicine; December 1998: Volume I, Issue 15; 1-2*

Atherosclerotic Aortic Disease as a source of embolic infarct; Bursell, John P., Odderson, I. and **Dunn, J.**; *Journal of Neurovascular Disease* 1996; 1; 2: 35-38

Intracerebral Bacillary Angiomatosis in a patient infected with HIV; Spach, D., Panther, L., Thorning, D., **Dunn, J.** Plorde, J.L., Miller, R.; *Annals of Internal Medicine;* 1992: 116; 740-743

Abstracts, posters and non-peer reviewed publications:

Assessment and Management Strategies for Relapsing Multiple Sclerosis Patients with Breakthrough Disease and Suboptimal Treatment Response; **Dunn J.**; Clin-Topics; January 2017; FCH-US-2262; pages 1-6

Alemtuzumab Significantly Improves Disability in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy as Assessed Using a Novel, Composite Measure of Confirmed Disability Improvement: Results from CARE-MS II; Singer B., **Dunn J.**, Izquierdo G., Thangavelu K., Mittal A., Pozzilli C., on behalf of MS-CARE II Investigators; 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); London, England, UK: 14-17 Sept 2016

T cell-driven dimethyl fumarate induced lymphopenia in patients with Multiple Sclerosis; Lee J-M, Lock, C., Ho, P and **Dunn J.**; Consortium of Multiple Sclerosis Centers annual meeting; National Harbor, Maryland: 2 June 2016

T cell-driven dimethyl fumarate induced lymphopenia in patients with MS; Lee, J-M, and **Dunn, J.E.**; PACTRIMS; 20 Nov 2015: Seoul, South Korea

Characteristics of leukocyte recovery following treatment with humanized anti-CD52 (alemtuzumab/Lemtrada) in multiple sclerosis
W. Gilmore, B.T. Lund, A. Traboulsee, A. Javed, **J.E. Dunn**, L.P. Weiner, P. Li, E.E. Kelland, A.M. Levy; ECTRIMS; 9 October 2015: Barcelona, Spain

The Utility of Magnetic Resonance Imaging in Multiple Sclerosis;
Dunn, J.; PACTRIMS Pan-Asian Committee for Treatment and Research in Multiple Sclerosis; 7 Nov 2014: Taipei, Taiwan

Discovery of a novel peripheral blood B cell signature of interferon beta therapy in MS:
Schubert R.D., Abraham P., Goodyear A., Steinman L., Senior authors: **Dunn J.**, Axtell R.; Stanford University School of Medicine Neuroscience Forum; Stanford, CA: 7 June 2013

Analysis of B Cell Subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy Reveals Modulation of CD19⁺CD24^{hi}CD38^{hi} Cells With Implications for the Diagnosis and Monitoring of MS
Schubert R., Goodyear A., Abraham P., Dunn C., Steinman L.; Senior authors: **Dunn J.** and Axtell R.; American Academy of Neurology Annual meeting abstract # P03.224; San Diego, CA: 19 March 2013

MRI Characteristics of CNS Demyelinating Disease in Ethnic Indian Patients;

Hua, Le H., Lee, Jong-mi, **Dunn J.**; Consortium of Multiple Sclerosis Centers CMSC Annual Conference; Montreal, Canada: 2011

MRI Characteristics of CNS Demyelinating Disease in those of Indian Ethnicity; Hua L., Lee J. and **Dunn J.**; Stanford University School of Medicine Neuroscience Forum; Stanford, CA; 13 May 2011

Clinical Trials in Multiple Sclerosis, developments and challenges: **CHOICE Study Investigators**: *ECTRIMS September 2007*; Prague, Czech Republic

The Modified Rankin Score as a measure of self report in MS using baseline assessments; Colfield S. and the **CombiRx Investigator Group**; *ECTRIMS 2007*; Prague, Czechoslovakia

Daclizumab in patients with active relapsing Multiple Sclerosis on concurrent interferon beta therapy Week 24 data Phase II; Montalban X, Kaufman M, Wynn D et the **CHOICE Study Investigators**: *ECTRIMS October 2007*; S18

Analyzing relapse assessment in CombiRx; Cutter et al, **CombiRx Investigator Group**; *ECTRIMS 2007*; Prague, Czechoslovakia

Mitoxantrone as induction followed by Glatiramer Acetate compared to Glatiramer Acetate monotherapy in relapsing Multiple Sclerosis; Vollmer, T., Panitch, H., Bar-Or, A., **Dunn, J.**, Freedman, M., Gazda, S.K., Campognolo, D. and Arnold, D.; *ECTRIMS 2006*; Madrid, Spain

Safety and tolerability of Glatiramer Acetate in pediatric patients with relapsing remitting Multiple Sclerosis; Krupp, L., Banwell, B., Picone, M., **Dunn, J.**, Weinstock-Guttman, B., and Pardo, L.: *ECTRIMS 2005*; Thessaloniki, Greece

Comprehensive outpatient management of patients with Multiple Sclerosis; Odderson, I.R., and **Dunn, J.**; *RIMS MS Symposium; May 2001*; 7th Annual RIMS Conference: Copenhagen, Denmark; May 2001

Novantrone in the treatment of Multiple Sclerosis; **Dunn, J.**, Kita, M. Lucas, S., Bowen, J. and the Pacific Northwest Alliance of MS Centers; *Alliance News; Fall 2001*; 1-3

Greater Washington Chapter Clinical Advisory Committee Statement on Procarin; Bowen, J., **Dunn, J.**, Kraft, G.H., Ratley, G., Shilling, J., Smith, C. and Thompson, L.; *Health Care Connection: Fall 1999: 1, Issue 1*; 1-2

Stroke: Acute Treatment and Prevention; 17th Annual University of Washington Review Course in Physical Medicine and Rehabilitation; Odderson, I., **Dunn, J.** et al; March 1996

Sponsored Clinical Research/Clinical Trials (Active):

Principal Investigator, NARCRMS Toward the Development of a National Longitudinal Data Base in Multiple Sclerosis. Sponsor: The Consortium of Multiple Sclerosis Centers (CMSC): 08/01/2017-07/31/2022

Protocol Director, Immunogenetics Studies in Multiple Sclerosis: Vitamin D Protocol Protocol IRB-25223: Sponsor NIH 2016-present

Principal Investigator,
VIDAMS: Vitamin D to ameliorate MS Trial: in collaboration with Johns Hopkins University (Study PI Ellen Mowry, MD) and NIH: 2012-present

Investigator,
Blood Repository to identify biomarkers in Multiple Sclerosis and Neuromyelitis Optica (in collaboration with Larry Steinman, MD); Stanford University: Stanford, CA: 2014-present

Co-Principal Investigator,
Blood and CSF Repository to Identify Biomarkers in Multiple Sclerosis (in collaboration with May Han, MD; Stanford University; Stanford, CA): Stanford Protocol # 16691; 9/09-present

Investigator,
Analysis of antibodies and immune responses in demyelinating disease (in collaboration with Bill Robinson, MD, PhD): ID: IRB-34529; 2015-present

Protocol Director,
Lymphocyte subset analysis of dimethyl fumarate associated lymphopenia; Stanford expedited protocol # 34592: 17 July 2015- 30 June 2018

Protocol Director,
7T MRI Characterization of Multiple Sclerosis and Demyelinating Diseases, submitted for IRB review: August 2014

Protocol Director,
Understanding Participation of Racial and Ethnic Groups in Multiple Sclerosis Clinical Trials; Stanford IRB Protocol # 29294: 07 March 2014-28 Feb 2015

Principal Investigator,
A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis. Protocol WA21093/A; Sponsor Genentech-Hoffman-LaRoche: June 2012-present

Principal Investigator;

An open label extension study of safety and tolerability of intravenous alemtuzumab (Lemtrada) in patients with relapsing-remitting Multiple Sclerosis who have relapsed on therapy; extension study of Protocol # CAMMS32400597; Sponsor Genzyme Corporation; Cambridge, MA: 01 Nov 2011-01 Nov 2014

Principal Investigator,

Multicenter, randomized, double blind parallel group extension to study AC-058B202 to investigate the long term safety, tolerability, and efficacy of 10, 20 and 40 mg/day ACT-128800 (Ponesimod), an oral S1P1 receptor agonist, in patients with relapsing remitting Multiple Sclerosis; Sponsor Actelion: 19 Feb 2010-present

Protocol Director,

Immune Modulation by Alemtuzumab in Multiple Sclerosis (in collaboration with Wendy Gilmore, PhD; USC; Los Angeles, CA): Stanford Protocol # 16988; 10/09-2015

Co-Investigator,

The Neuroanatomy of Pseudobulbar Affect (in collaboration with Josef Parvizi, MD, PhD; Stanford University; Stanford, CA): Stanford Protocol # 15264; 7/09-2012

Sponsored Clinical Research/ Clinical Trials (Past or Completed):

Principal Investigator;

A Phase III Randomized, Rater and Dose Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three Times weekly Subcutaneous Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis who have Relapsed on Therapy; Protocol CAMMS32400597; Sponsor Genzyme Corporation; Cambridge, MA; Stanford Protocol # 16988: 08 May 2009-07 May 2012

Principal Investigator,

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Three Doses of ACT-128800 (Ponesimod), an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients with Relapsing-remitting Multiple Sclerosis; Sponsor Actelion: 7 Dec 2010-6 Dec 2012

Principal Investigator,

JC Virus Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: The STRATIFY-2 Study. Stanford Protocol #18841; Sponsor Biogen-Idec: 14 June 2011-31 May 2012

Co-Principal Investigator and Protocol Director,

Protocol Title: A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating Diseases; Sponsor: Accelerated Cure Project; Stanford Protocol 17667: 01 Mar 2010-July 2013

Principal Investigator;

A Multi-Center, Double Blind, Randomized Study, Comparing the Combined Use of Interferon Beta 1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis; CombiRx Protocol, Sponsor NIH; Bethesda, MD; September 2005-February 2008

Principal Investigator;

A Multi-Center, Randomized, Double Blinded, Placebo Controlled Study of Subcutaneous Tovaxin in Subjects with Clinically Isolated Syndrome or Relapsing Remitting Multiple Sclerosis; The "TERMS" Study; Sponsor Opexa Therapeutics; The Woodlands, Texas; November 2006-February 2008

Sub-Investigator;

A Double Blind, Randomized Multicenter Placebo Controlled Parallel Group Study Comparing Efficacy and Safety of FTY720 (Fingolimod) Administered Orally Versus Placebo in Patients with Relapsing Remitting Multiple Sclerosis; Sponsor Novartis Pharma AG; Switzerland; October 2007-February 2008

Sub-Investigator;

Open Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients with Multiple Sclerosis who Participated in the MS-F204 Trial; Acorda Therapeutics; November 2007-February 2008

Principal Investigator;

A Phase II Randomized, Double Blinded, Placebo Controlled, Multi-Center Dose Ranging Study of Subcutaneous Daclizumab in Patients with Active Relapsing Forms of Multiple Sclerosis; Protocol DAC-1012 CHOICE Study; Sponsor PDL Biopharma; October 2005-November 2007

Sub-Investigator;

Phase I, Double Blind Placebo Controlled, Dose Escalation Study of the Safety of RTL1000 in Subjects with Relapsing Remitting Multiple Sclerosis or Secondary Progressive Multiple Sclerosis; Sponsor Artielle Immunotherapeutics, Inc.; Tigard, Oregon; May 2007-February 2008

Principal Investigator;

A Multi-Center, Randomized, Double Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of 40 mg Glatiramer Acetate in the Treatment of Relapsing

Remitting Multiple Sclerosis Patients; Protocol # 9006; Sponsor Teva Neuroscience; 7/04-11/05

Principal Investigator;

A Multi-Center, Randomized Double Blind Parallel Group Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects with Multiple Sclerosis Who Have Completed Studies C-1801, C-1802 and C-1803; Protocol # C-1808; Sponsor Biogen-Idec; Cambridge, MA; 7/04-10/05

Principal Investigator;

A Multi-Centered Two Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone) Preceding Treatment with Glatiramer Acetate versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis; Protocol #NC-100; Sponsor Teva Neuroscience; North Wales, PA; 8/04-2/06

Principal Investigator;

A Retrospective Study to Evaluate the Safety and Tolerability of Copaxone for Injection in Pediatric patients with Relapsing Remitting Multiple Sclerosis; Protocol # PM012; Sponsor Teva Neuroscience; North Wales, PA; 8/04-3/05

Sub-Investigator;

A Double Blind, Placebo Controlled 13 Week Parallel Group Study to Evaluate the Efficacy, Safety and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis; Protocol # MS-F301; Sponsor Acorda Therapeutics; Hawthorne, NY; 6/04-2/08

Principal Investigator;

A Phase IV Study of Copolymer I in the Treatment of Multiple Sclerosis; Protocol Cop-I; Sponsor Teva Marion Partners; Kansas City, MO; 1994-1996

Inventions and Intellectual Property:

Inventor, "Marker for determination of patient responsiveness;" **Dunn, J.**, Axtell R., Schubert R. Stanford researchers have developed a test that measures transitional B cells in peripheral blood for use in determining patient responsiveness to Multiple Sclerosis (MS) treatments. US patent pending: 14/781,885; filed PCT priority 04 April 2014

Special Materials:

Moderator, "Candid Conversations, real world insights on Relapsing Multiple Sclerosis;" **Dunn J.**, Cabot A., O'Connell B., Katz, J. : filmed in Brooklyn, NY: 2016

https://www.tecfiderahcp.com/en_us/home/real-tec/real-tec.html?cid=off-print-advertorialpg2-explorerealt-tec-rt-vanityurl-tec16offline#roundtable-setting-expectations-001

Commentator, Everydayhealth.com

Does Obesity Raise the risk of Multiple Sclerosis? <http://www.everydayhealth.com/multiple-sclerosis/obesity-raise-risk-multiple-sclerosis>: 11 Jan 2016

Expert Faculty, Pan-European Union Broadcast: “Dimethyl Fumarate for Relapsing Remitting Multiple Sclerosis;” media broadcast to 14 member countries of the EU; HBO Studios; New York, New York: 12 March 2014

Expert Faculty, Visiting Professor CME: Peer-to-Peer Academic Updates, Multiple Sclerosis Year in Review; national webcam, PRIME Education Inc., Tamarac, FL: 11/12-01/13

Multiple Sclerosis Residency Core Curriculum; **Dunn J.**, Vokaty W. Lisak R. and the American Academy of Neurology MS Education Task Force; 2012-2013
<http://www.aan.com/go/about/sections/curriculaMS> Section

MS On The Rise: *CBS Evening News*; cbsnews.com/ Up To The Minute/ MS: April 2007

Presentations and Media (2011-2017 only):

Platform Faculty, “Multiple Sclerosis Update 2017;” California Neurology Society; San Francisco, CA: 27 May 2017

Platform Faculty, “NMO 101;” Stanford Medicine NMO CIRCLES Patient Day; Stanford University LKSC Center; Stanford, CA: 28 Jan 2017

Distinguished Faculty, “Immunology: A Review of the Fundamentals,” American Headache Society Annual Symposium; Scottsdale, AZ: 18 Nov 2016

Panel Chair, “Evaluating Therapeutic Success”; Dunn J., Singer P.A., Liebman, H. & Appel G.; Palo Alto, CA: 10 November 2016

Keynote Speaker, “Specialty MS Patient Care: A Symposium for Developing Clinicians”; San Francisco, CA: 26 Oct 2016

Grand Rounds Presenter, “Multiple Sclerosis Update 2016;” California Pacific Medical Center; San Francisco, CA: 28 April 2016

Platform faculty, “Making the Most out of Your Neurology Clerkship: The Stanford Experience”; Navigating Your Career, American Academy of Neurology Annual Meeting; Vancouver, British Columbia, Canada: 20 April 2016

Platform Faculty, “Rebounding from Chronic Disease”; Oracle Arena; Oakland, CA: 6 Apr 2016

Advisory Board, “Ethnic Minority Populations and Multiple Sclerosis”; Dallas, TX: 5 Dec 2015

Platform Faculty, “Is it Demyelinating Disease?” 6th Annual Breakthroughs in Neurologic Therapies Symposium; Stanford Medicine; San Francisco, CA: 20 Nov 2015

Neurology Grand Rounds, “A New Era: Immunocompetent PML;” McGranahan T., Dunn J.; Stanford Department of Neurology & Neurological Sciences: 21 Aug 2015; Stanford, CA

Platform faculty, “Alemtuzumab extension data;” Dallas, TX: 17 Jan 2015

Platform Faculty, “The Utility of Magnetic Resonance Imaging in Multiple Sclerosis;” 7th Annual Congress of the Pan-Asian Committee for Treatment & Research in Multiple Sclerosis (PACTRIMS); Taipei, Taiwan: 6 November 2014

Platform Faculty, “An Approach to the Diagnosis of Transverse Myelitis;” 5th Annual Breakthroughs in Neurologic Therapies Symposium; Stanford Medicine; San Francisco, CA: 31 Oct 2014

Faculty, 6th Annual Updates fromECTRIMS-ACTRIMS: Highlights in Treatment and Research of MS; PRIME CME 1.5 AMA; San Francisco, CA: 29 Sep 2014

Platform Faculty, “Treatment Decisions at the intersection of trials and practice;” ECTRIMS-ACTRIMS Symposium (> 2500 attendees > 80 countries); Boston, MA: 12 Sep 2014

Grand Rounds, “Multiple Sclerosis Update;” Dominican Hospital; Santa Cruz, CA: 8 Aug 2014

Invited Keynote Speaker, Mellen Center Update in Multiple Sclerosis, Cleveland Clinic Foundation; Cleveland, Ohio: 27 June 2014

Professor’s Rounds, Center for Multiple Sclerosis & Brain Research; Tel Aviv, Haifa, Israel: 22-24 June 2014

Platform Faculty, “Multiple Sclerosis Highlights in the Field;” American Academy of Neurology annual meeting, Highlights platform session; PCC 113 ABC; Philadelphia, PA: 30 April 2014

Faculty, MS Experts Consensus Summit: “No Evidence of Disease Activity” as a treatment target in Multiple Sclerosis; Cleveland Clinic; Las Vega, Nevada: 12-14 December 2013

5th Annual Updates fromECTRIMS: Highlights in Treatment and Research of Multiple Sclerosis; PRIME CME faculty; Fresno, CA: 13 Nov 2013

Best Practices in the treatment and management of Multiple Sclerosis: Translating research into real practice through case studies; Multiple Sclerosis Association of America: Sacramento & Palo Alto, CA: November 2013

Risks of New and Emerging Therapies for Multiple Sclerosis; Faculty Presenter, 4th Annual Breakthroughs in Neurologic Therapies: CME Conference sponsored by Stanford University School of Medicine; San Francisco, CA: 1 Nov 2013

Multiple Sclerosis Symposium; keynote speaker; Sydney, Australia (Australian Government temporary work visa for highly specialized work): 13 September 2013

A New Oral Therapy for Multiple Sclerosis; Faculty, national Satellite Broadcast Event: HBO Television Studios; New York, NY: 9 May 2013

Cutting Edge Techniques in Stroke and MS Management; San Francisco 49ers Headquarters with Stanford Hospital & Clinics; Santa Clara, CA: 2 May 2013

Tecfidera A New Treatment for Multiple Sclerosis; Faculty Presenter, National Consultants' Meeting: Scottsdale, AZ: 20 April 2013

Medical Grand Rounds, "Paradigm Shift in Conception and Management of Multiple Sclerosis;" Stanford Department of Medicine, Stanford University School of Medicine: 12 Jan 2013

Peer-to-Peer Academic Debate: How Do We Manage MS Patients in Light of the Rapidly Changing Treatment Paradigm: PRIME CME national webinar: 17 Jan 2013

Recent Changes in the MS Treatment Landscape; 3rd Annual Breakthroughs in Neurologic Therapies CME Program, sponsored by Stanford University School of Medicine; San Francisco, CA: 10 Nov 2012

MS Expert Forum; Dallas, TX: 3 Nov 2012

Assessing Suboptimal Response to treatment in Patients with relapsing Forms of MS; Multiple Sclerosis Scientific Roundtable: San Jose, CA: 24 Oct 2012

The TEMSO Study: Study Design and Efficacy; Dallas, TX: 15 Sep 2012

Introduction to Multiple Sclerosis: Principles and Practice; Stanford University School of Medicine Primary Care Associates program; Stanford, CA: 13 Aug 2012

The Brave New World of MS Treatment; Advances in Neurosciences Sixth Annual Bay Area Symposium; Washington Hospital Healthcare System: Fremont, CA: 14 July 2012

CONFIRM Trial: Dimethylfumarate and reference comparator in the treatment of relapsing Multiple Sclerosis; Southwest US Regional Advisory Meeting: Dallas, Texas: 6/8-9/2012

Factors Influencing Benefit-Risk Decisions in the Clinical management of Multiple Sclerosis; Challenging Case Series: San Jose, CA: June 2012

Newest Science and Strategies in Multiple Sclerosis in Medication Management; PRIME CME Program; San Mateo, CA: 16 Feb 2012

Personalized Medicine in Multiple Sclerosis, National Advisory Committee Meeting: Biogen-Idec Medical Affairs; Miami, FL: 10-12 Feb 2012

Determination of Efficacy and Safety of Oral Fumarate in Relapsing Remitting Multiple Sclerosis: Preliminary Review of the DEFINE Study (BG-12 in MS); San Francisco, CA: 4 February 2012

Updates fromECTRIMS: Highlights from the European and Americas Committees for Treatment and Research in Multiple Sclerosis: PRIME CME Program; Fresno, CA: 25 Jan 2012

Updates fromECTRIMS: Highlights from the European and Americas Committees for Treatment and Research in Multiple Sclerosis: PRIME CME Program; Sacramento, CA: 18 Jan 2012

Interpreting Outcomes and End Points in MS Clinical Trials: Implications of Relapse Rate Reduction, Neuroimaging and Disability Metrics; CME Education Resources Southwest Regional Conference: Phoenix, AZ: 17 Dec 2011

Review and Analysis of Teriflunomide and the Clinical Implications of the TEMSO Trial for Multiple Sclerosis Patients; ITA Advisory Board: Phoenix, AZ: 11 December 2011

Emerging Options for Initial Therapy for Multiple Sclerosis: Immunomodulation and Immunosuppression: When, Why, In Whom?; CME Education Resources; Neurotherapy in MS National Faculty Consortium: San Francisco, CA: 3 Dec 2011

The Changing Face of Multiple Sclerosis; 2nd Annual Breakthroughs in Neurologic Therapies Symposium; Stanford University School of Medicine Regional Symposium; San Francisco, CA: 8 Oct 2011

How to do a Lumbar Puncture; Department of Neurology Housestaff Didactic Series. Stanford University School of Medicine LKSC Simulation Center: Stanford, CA: 17 Aug 2011

Emerging Multiple Sclerosis Therapies; National MS Society: Santa Clara, CA: 7/23/2011

Risk Stratification Strategies to Optimize Alignment of Oral Therapies with Specific MS Patient Subgroups; CMEducation Resources: A CME activity sponsored by the University of Massachusetts Medical School; San Francisco, CA: 6/25/2011

The impact of anti-jc antibody assay by two step ELISA method on treatment choice for Multiple Sclerosis; Salt Lake City, Utah: 5/4/11

Multiple Sclerosis Update; 63rd Annual Meeting of the San Francisco Neurological Society; Monterey, California: 2/26/2011

Post-degree Honors and Awards:

- 2017 Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine; Stanford University School of Medicine
- 2017 Best Doctor, US News & World Report Health Care Rankings, 2017; <http://health.usnews.com/doctors/jeffrey-dunn-360709>
- 2017 Castle Connolly Top Doctor for 5 Years; peer nominated, among best in specialty
- 2012-2017 Castle Connolly Top Doctor: 2012, 2013, 2014, 2015, 2016, 2017
- 2016-2017 Neurology Clerkship Student Teaching Award; Stanford University
- 2015-2016 Neurology Clerkship Student Teaching Award; Stanford University
- 2014-2015 Neurology Clerkship Student Teaching Award; Stanford University
- 2013-2014 Neurology Clerkship Student Teaching Award; Stanford University
- 2014 America's Top Physicians; Consumers' Research Council of America
- 2013-2014 Neurology Clerkship Student Teaching Award; Stanford University
- 2012-2013 Neurology Clerkship Student Teaching Award; Stanford University
- 2013 Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching; Stanford University School of Medicine
- 2012-2013 Excellence in Teaching Award, Stanford University School of Medicine
- 2012-2013 AUPN Recruitment Award for Neurology Clerkship among US medical schools
- 2012-2013 Top Doctors; US News & World Report National Rankings
- 2011-2012 Excellence in Teaching Award, Stanford University School of Medicine
- 2011-2012 Neurology Clerkship Student Teaching Award; Stanford University
- 2012, 2013 America's Top Physicians; Consumers' Research Council of America
- 2011 Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine; Stanford University School of Medicine
- 2011 Association of University Professors of Neurology AUPN Recruitment Award, highest percentage of graduating medical students proceeding to postgraduate training in the clinical neurosciences; Stanford University School of Medicine
- 2010-2011 Neurology Clerkship Student Teaching Award; Stanford University
- 2009-2010 Excellence in teaching Award, Stanford University School of Medicine

2009-2010 Neurology Clerkship Student Teaching Award; Stanford University
2010 Guide to America's Top Physicians; Consumers' Research Council of America
2008-2009 Lysia Forno Award for Teaching Excellence to Neurology housestaff
2008-2009 Neurology Clerkship Student Teaching Award; Stanford University
1998-2007 America's Top Rated Physicians, *Guide to Top Doctors*
2005 Finalist, Pacific Northwest Writers' Association for best screenplay
2004 Seattle's Top Doctors for Women, *Seattle Magazine*
1996 Subject of biographical inclusion, *Who's Who in America*

Philanthropy and Community Service:

Orphan Outreach,

Charitable medical care to children orphaned by the African AIDS crisis: Mathare slums outside Nairobi, Kenya; and Bungoma, Kenya: July 2017: www.orphanoutreach.org

Buck/Cardinal Club, Stanford University

To help Stanford Athletics field 36 top-level varsity sports teams and support student athletes; Stanford University Department of Athletics; Stanford, CA: 2013-2016

Charter Hill Society, UC Berkeley

For extraordinary commitment to preserving and enhancing excellence in education; UC Berkeley; Berkeley, CA: 2011-2015

Co-Chair, Legacy and Key Donor Capital Campaign

Co-chaired capital campaign that raised \$7.2M to build the Halvorson Recreation Center; Redmond, WA; 2005

President and Chief Medical Officer, MS Hub Medical Group

Successfully raised more than \$2M to achieve mission of MS Hub Foundation in establishing major regional MS and Neuroscience Institute; Seattle, WA 2004-2005

Board of Directors;

Washington Cathedral; Redmond, WA; 2004-2007 (3 year term)

Emerald Award Winner for Outstanding Vision in Community Service;

Washington Cathedral; Redmond, WA 1999